AR023986A1 - 3-piridil-4-arilpirroles sustituidos y metodos terapeuticos y profilacticos relacionados - Google Patents

3-piridil-4-arilpirroles sustituidos y metodos terapeuticos y profilacticos relacionados

Info

Publication number
AR023986A1
AR023986A1 ARP000102325A ARP000102325A AR023986A1 AR 023986 A1 AR023986 A1 AR 023986A1 AR P000102325 A ARP000102325 A AR P000102325A AR P000102325 A ARP000102325 A AR P000102325A AR 023986 A1 AR023986 A1 AR 023986A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
hydrogen
group
phenyl
Prior art date
Application number
ARP000102325A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR023986A1 publication Critical patent/AR023986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Obesity (AREA)

Abstract

Esta invencion proporciona nuevos 3-piridil-4-arilpirroles sustituidos, o una sal farmacéuticamente aceptable del mismo, en donde (a)R1 se selecciona entreel grupo que consiste de (i) hidrogeno, (ii) alquilo C1-5(iii) alquilamino (C1-5 sustituido o insustituido, (iv) heterociclo alquilo C1-5 que contiene Nseleccionado entre tiazolidina, piperidina, morfolina piperazina, tiomorfolina, pirrolidina , tiazina, pirrol, e imidazol (v) fenilo, (vi) feniloindependientemente sustituido con uno o más de alquilo C1-5, amino, amino sustituido, nitro, nitrilo, sulfona y (vii) piridina; (b) R2 se selecciona entre elgrupo que consiste de (i) hidrogeno, (ii)(CH2)3OH, (iii)alquil C1-5, fenilo sustituido o insustituido y (iv) heterociclo alquilo C1-5 que contiene N,seleccionado entre tiazolidina, piperidina, morfolina, piperazina, tiomorfolina, pirrolidina, tiazina, pirrol e imidazol, (c) R3 es uno o más sustituyentesindependientemente seleccionados entre el grupo que consiste de hidrogeno, halogeno, metoxi, nitro, trifluormetilo, hidroxi, dimetilamino y metilsulfoxido y(d) X es ya sea C o N y composiciones farmacéuticas que los comprenden, utiles para el tratamiento de desordenes que se mejoran por medio de la reduccion de laproduccion de TNF-alfay/o de la actividad de p38 en células apropiadas. Esta invencion también proporciona métodos terapéuticos y profilácticos utilizando laspresentes composiciones farmacéuticas.
ARP000102325A 1999-05-14 2000-05-15 3-piridil-4-arilpirroles sustituidos y metodos terapeuticos y profilacticos relacionados AR023986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13413999P 1999-05-14 1999-05-14

Publications (1)

Publication Number Publication Date
AR023986A1 true AR023986A1 (es) 2002-09-04

Family

ID=22461942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102325A AR023986A1 (es) 1999-05-14 2000-05-15 3-piridil-4-arilpirroles sustituidos y metodos terapeuticos y profilacticos relacionados

Country Status (23)

Country Link
US (1) US6562843B1 (es)
EP (1) EP1178981B1 (es)
JP (1) JP2002544272A (es)
KR (1) KR20010114267A (es)
CN (1) CN1210273C (es)
AR (1) AR023986A1 (es)
AT (1) ATE243690T1 (es)
AU (1) AU777702B2 (es)
BR (1) BR0010560A (es)
CA (1) CA2374559A1 (es)
DE (1) DE60003550T2 (es)
DK (1) DK1178981T3 (es)
ES (1) ES2200878T3 (es)
HK (1) HK1042901B (es)
IL (1) IL146465A0 (es)
MX (1) MXPA01011720A (es)
MY (1) MY127675A (es)
NZ (1) NZ515531A (es)
PT (1) PT1178981E (es)
RU (1) RU2238940C2 (es)
TW (1) TWI229671B (es)
WO (1) WO2000069847A1 (es)
ZA (1) ZA200110271B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2005505562A (ja) * 2001-09-05 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのピリジルフランおよびピロール
WO2004029040A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
AU2004221881A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
US7612064B2 (en) * 2003-05-26 2009-11-03 Takeda Pharmaceutical Company Limited Sulfopyrroles
CA2535980A1 (en) * 2003-06-06 2005-01-06 The Trustees Of The University Of Pennsylvania P38 kinase inhibitor compositions and methods of use
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2007139781A2 (en) * 2006-05-23 2007-12-06 Cree Led Lighting Solutions, Inc. Lighting device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
AU705082B2 (en) * 1995-08-10 1999-05-13 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
CA2228050A1 (en) 1995-08-10 1997-02-20 Harold G. Selnick 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
JPH11514651A (ja) * 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
EP0912548A1 (en) * 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
EP1178981A1 (en) 2002-02-13
MXPA01011720A (es) 2003-10-14
US6562843B1 (en) 2003-05-13
NZ515531A (en) 2004-03-26
JP2002544272A (ja) 2002-12-24
TWI229671B (en) 2005-03-21
HK1042901B (zh) 2003-11-07
AU777702B2 (en) 2004-10-28
DE60003550D1 (de) 2003-07-31
CA2374559A1 (en) 2000-11-23
PT1178981E (pt) 2003-11-28
AU4677700A (en) 2000-12-05
KR20010114267A (ko) 2001-12-31
CN1361773A (zh) 2002-07-31
ZA200110271B (en) 2003-05-28
ES2200878T3 (es) 2004-03-16
RU2238940C2 (ru) 2004-10-27
CN1210273C (zh) 2005-07-13
WO2000069847A1 (en) 2000-11-23
DK1178981T3 (da) 2003-09-29
IL146465A0 (en) 2002-07-25
DE60003550T2 (de) 2004-04-15
EP1178981B1 (en) 2003-06-25
ATE243690T1 (de) 2003-07-15
HK1042901A1 (en) 2002-08-30
BR0010560A (pt) 2002-06-04
MY127675A (en) 2006-12-29

Similar Documents

Publication Publication Date Title
AR035557A1 (es) Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivado
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR031627A1 (es) Activadores heteroaromaticos fusionados de la glucoquinasa
NO921609L (no) Sulfonamider og deres medisinske anvendelse
DE60034961D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
NO20044592L (no) Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
AR003414A1 (es) Uso de derivados de imidazol [1,2-a]piridina -3-acetamida y una composicion farmaceutica que comprende tal derivado
SE9904176D0 (sv) New use
MY121778A (en) Benzosulfone derivatives
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
AR023986A1 (es) 3-piridil-4-arilpirroles sustituidos y metodos terapeuticos y profilacticos relacionados
NO972841L (no) Aryl- og heteroaryl-sulfonamidderivater, deres fremstilling og anvendelse som endotelinantagonister
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
NO20004089L (no) Nye triazolo(4,5-d)pyrimidinforbindelser
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
SE0202461D0 (sv) Novel compounds
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
AR028606A1 (es) Nuevos inhibidores de mmp-2/mmp-9

Legal Events

Date Code Title Description
FB Suspension of granting procedure